{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-111940","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.776989+00:00","generated_at":"2026-05-16T19:39:44.554280+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"confidence":"high","headline":"Marker Therapeutics reports Q3 net loss $2.0M; APOLLO study shows 66% ORR, 50% CR in NHL","bullets":["Cash $17.6M + restricted $1.4M; runway into Q3 2026; raised ~$10M via ATM.","Net loss $2.0M (improved from $2.3M YoY); R&D $2.3M (down from $3.5M).","APOLLO study: 66% ORR, 50% CR in 12 relapsed NHL patients; durable responses (≥6 months in 5); dose expansion ongoing.","First patient dosed in OTS RAPID study (MT-401) for AML/MDS; cGMP manufacturing pact with Cellipont.","Appointed Kathryn Penkus Corzo to Board; two ASH presentations scheduled Dec 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-111940","json":"https://secwatch.observer/filing/0001104659-25-111940.json","markdown":"https://secwatch.observer/filing/0001104659-25-111940.md","text":"https://secwatch.observer/filing/0001104659-25-111940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925111940/0001104659-25-111940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925111940/tm2530894d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:39:44.554280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}